United Therapeutics Shares Outstanding History (UTHR)
United Therapeutics reported 43.6M shares outstanding at the end of fiscal 2025.
View full United Therapeutics company overviewUnited Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 43.6M | −1.2M | −2.65% |
| 2024 | 2024-12-31 | 44.8M | −2.2M | −4.70% |
| 2023 | 2023-12-31 | 47.0M | 1.0M | +2.19% |
| 2022 | 2022-12-31 | 46.0M | 924,259 | +2.05% |
| 2021 | 2021-12-31 | 45.1M | 600,707 | +1.35% |
| 2020 | 2020-12-31 | 44.5M | 622,539 | +1.42% |
| 2019 | 2019-12-31 | 43.9M | 296,194 | +0.68% |
| 2018 | 2018-12-31 | 43.6M | 348,741 | +0.81% |
| 2017 | 2017-12-31 | 43.2M | 273,768 | +0.64% |
| 2016 | 2016-12-31 | 43.0M | −2.8M | −6.11% |
| 2015 | 2015-12-31 | 45.8M | −1.3M | −2.86% |
| 2014 | 2014-12-31 | 47.1M | −3.3M | −6.51% |
| 2013 | 2013-12-31 | 50.4M | 222,187 | +0.44% |
| 2012 | 2012-12-31 | 50.2M | −3.4M | −6.42% |
| 2011 | 2011-12-31 | 53.6M | −3.9M | −6.86% |
| 2010 | 2010-12-31 | 57.6M | 3.3M | +6.15% |
| 2009 | 2009-12-31 | 54.2M | — | — |
United Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 42.7M | −2.5M | −5.61% |
| Q1 2026 | 2026-03-31 | 42.2M | −2.9M | −6.47% |
| Q4 2025 | 2025-12-31 | 43.6M | −1.2M | −2.65% |
| Q3 2025 | 2025-09-30 | 42.9M | −1.7M | −3.84% |
| Q2 2025 | 2025-06-30 | 45.2M | 793,612 | +1.79% |
| Q1 2025 | 2025-03-31 | 45.1M | 870,034 | +1.97% |
| Q4 2024 | 2024-12-31 | 44.8M | −2.2M | −4.70% |
| Q3 2024 | 2024-09-30 | 44.6M | −2.4M | −5.04% |
| Q2 2024 | 2024-06-30 | 44.4M | −2.5M | −5.31% |
| Q1 2024 | 2024-03-31 | 44.2M | −2.5M | −5.34% |
| Q4 2023 | 2023-12-31 | 47.0M | 1.0M | +2.19% |
| Q3 2023 | 2023-09-30 | 47.0M | 1.4M | +3.11% |
| Q2 2023 | 2023-06-30 | 46.9M | 1.4M | +3.13% |
| Q1 2023 | 2023-03-31 | 46.7M | 1.4M | +3.12% |
| Q4 2022 | 2022-12-31 | 46.0M | 924,259 | +2.05% |
| Q3 2022 | 2022-09-30 | 45.6M | 541,598 | +1.20% |
| Q2 2022 | 2022-06-30 | 45.5M | 599,307 | +1.34% |
| Q1 2022 | 2022-03-31 | 45.3M | 498,850 | +1.11% |
| Q4 2021 | 2021-12-31 | 45.1M | 600,707 | +1.35% |
| Q3 2021 | 2021-09-30 | 45.0M | 581,562 | +1.31% |
| Q2 2021 | 2021-06-30 | 44.9M | 533,804 | +1.20% |
| Q1 2021 | 2021-03-31 | 44.8M | 786,550 | +1.79% |
| Q4 2020 | 2020-12-31 | 44.5M | 622,539 | +1.42% |
| Q3 2020 | 2020-09-30 | 44.4M | 559,332 | +1.27% |
| Q2 2020 | 2020-06-30 | 44.4M | 508,380 | +1.16% |
| Q1 2020 | 2020-03-31 | 44.0M | 196,347 | +0.45% |
| Q4 2019 | 2019-12-31 | 43.9M | 296,194 | +0.68% |
| Q3 2019 | 2019-09-30 | 43.9M | 294,569 | +0.68% |
| Q2 2019 | 2019-06-30 | 43.8M | 286,125 | +0.66% |
| Q1 2019 | 2019-03-31 | 43.8M | 369,807 | +0.85% |
| Q4 2018 | 2018-12-31 | 43.6M | 348,741 | +0.81% |
| Q3 2018 · Sep 30 | 2018-09-30 | 43.6M | 379,334 | +0.88% |
| Q2 2018 | 2018-06-30 | 43.6M | 126,267 | +0.29% |
| Q1 2018 | 2018-03-31 | 43.4M | −1.6M | −3.59% |
| Q4 2017 | 2017-12-31 | 43.2M | 273,768 | +0.64% |
| Q3 2017 | 2017-09-30 | 43.2M | 544,669 | +1.28% |
| Q2 2017 | 2017-06-30 | 43.4M | −296,489 | −0.68% |
| Q1 2017 | 2017-03-31 | 45.1M | 168,230 | +0.37% |
| Q4 2016 | 2016-12-31 | 43.0M | −2.8M | −6.11% |
| Q3 2016 | 2016-09-30 | 42.7M | −2.9M | −6.41% |
| Q2 2016 | 2016-06-30 | 43.7M | −2.0M | −4.29% |
| Q1 2016 | 2016-03-31 | 44.9M | −1.5M | −3.20% |
| Q4 2015 | 2015-12-31 | 45.8M | −1.3M | −2.86% |
| Q3 2015 | 2015-09-30 | 45.6M | −1.9M | −3.91% |
| Q2 2015 | 2015-06-30 | 45.7M | −1.5M | −3.25% |
| Q1 2015 | 2015-03-31 | 46.4M | −3.3M | −6.62% |
| Q4 2014 | 2014-12-31 | 47.1M | −3.3M | −6.51% |
| Q3 2014 | 2014-09-30 | 47.4M | −2.7M | −5.46% |
| Q2 2014 | 2014-06-30 | 47.2M | −2.6M | −5.24% |
| Q1 2014 | 2014-03-31 | 49.7M | −586,745 | −1.17% |
| Q4 2013 | 2013-12-31 | 50.4M | 222,187 | +0.44% |
| Q3 2013 | 2013-09-30 | 50.2M | −985,292 | −1.93% |
| Q2 2013 | 2013-06-30 | 49.8M | −1.9M | −3.60% |
| Q1 2013 | 2013-03-31 | 50.2M | −3.4M | −6.40% |
| Q4 2012 | 2012-12-31 | 50.2M | −3.4M | −6.42% |
| Q3 2012 | 2012-09-30 | 51.2M | −7.2M | −12.29% |
| Q2 2012 | 2012-06-30 | 51.7M | −6.6M | −11.33% |
| Q1 2012 | 2012-03-31 | 53.7M | −4.3M | −7.43% |
| Q4 2011 | 2011-12-31 | 53.6M | −3.9M | −6.86% |
| Q3 2011 | 2011-09-30 | 58.3M | 1.6M | +2.74% |
| Q2 2011 | 2011-06-30 | 58.3M | 1.9M | +3.41% |
| Q1 2011 | 2011-03-31 | 58.0M | 3.8M | +6.95% |
| Q4 2010 | 2010-12-31 | 57.6M | — | — |
| Q3 2010 | 2010-09-30 | 56.8M | — | — |
| Q2 2010 | 2010-06-30 | 56.4M | — | — |
| Q4 2009 | 2009-12-31 | 54.2M | — | — |
United Therapeutics shares outstanding trends
Over the last five reported fiscal years, United Therapeutics's shares outstanding moved from 44.5M to 43.6M, a change of −863,933. The latest reported quarter, Q2 2026, shows 42.7M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review United Therapeutics filings at SEC.gov ↗